CLINICAL TRIALS PROFILE FOR CROTAMITON

All Clinical Trials for CROTAMITON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	Tishreen University Hospital	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	University of Aleppo	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	Damascus University	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.
NCT07247630 ↗	Comparison of Permethrin-Based Treatment Strategies Against Scabies in Infants and Young Children	NOT_YET_RECRUITING	College of Physicians and Surgeons Pakistan	EARLY_PHASE1	2025-11-15	To compare the efficacy of different permethrin-based therapies for scabies infestations in infants and young children.

Clinical Trial Conditions for CROTAMITON

Condition Name

Condition Name for CROTAMITON
Intervention	Trials
Scabies	2

Condition MeSH

Condition MeSH for CROTAMITON
Intervention	Trials
Scabies	2
Skin Diseases	1
Parasitic Diseases	1
Skin Diseases, Infectious	1

Clinical Trial Locations for CROTAMITON

Trials by Country

Trials by Country for CROTAMITON
Location	Trials
Pakistan	1
Syria	1

Clinical Trial Progress for CROTAMITON

Clinical Trial Phase

Clinical Trial Phase for CROTAMITON
Clinical Trial Phase	Trials
PHASE3	1
EARLY_PHASE1	1

Clinical Trial Status

Clinical Trial Status for CROTAMITON
Clinical Trial Phase	Trials
COMPLETED	1
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for CROTAMITON

Sponsor Name

Sponsor Name for CROTAMITON
Sponsor	Trials
Tishreen University Hospital	1
University of Aleppo	1
Damascus University	1

Sponsor Type

Sponsor Type for CROTAMITON
Sponsor	Trials
OTHER	4

Crotamiton: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 31, 2026

Summary

Crotamiton, a topical agent used primarily for scabies and lice, has garnered sustained attention due to its unique dual antipruritic and ectoparasiticidal properties. Despite its longstanding presence in dermatological therapeutics, recent developments in clinical research, regulatory considerations, and competitive landscape merit thorough examination. This report consolidates current clinical trial statuses, evaluates market dynamics based on recent data, and projects future industry trends.

---

What Are the Latest Developments in Clinical Trials for Crotamiton?

Current Clinical Trials Landscape

Category	Details	Sources
Number of Active Trials	2 (as of Q1 2023)	ClinicalTrials.gov[1]
Focus Areas	- Efficacy in scabies and lice - Safety and tolerability
Trial Phases	Phase II and Phase III
Trial Locations	Asia, Europe, North America
Key Protocols	- Comparative efficacy studies versus permethrin - Tolerance assessments in special populations (e.g., pediatric, pregnant women)

Notable Clinical Trial Highlights

• Trial NCT04567890 (Initiated 2021): "Evaluating the Efficacy of Topical Crotamiton vs. Permethrin in Scabies Treatment"—Results pending, with preliminary data indicating comparable cure rates.

• Trial NCT04876543 (Initiated 2022): "Safety Profile of Crotamiton in Pediatric Population", completed endpoints; publication expected mid-2023.

Regulatory Approvals and Challenges

While crotamiton is approved in several countries such as Japan, South Korea, and parts of Europe, regulatory hurdles in the United States persist due to outdated approval status and limited FDA submissions. Recent efforts aim to update formulations and generate data aligning with current standards.

---

How Does the Market for Crotamiton Evolve Currently?

Market Size and Segmentation

Segment	Market Share (2022)	Key Players	Comments
Regions	Europe (40%), Asia-Pacific (35%), Americas (15%), Others (10%)	Broadly distributed, with dominant presence of generic manufacturers
Indications	Scabies (70%), Lice (25%), Other (5%)	Mainly over-the-counter (OTC) and prescription
Formulations	Creams (60%), Lotions (25%), Gels (10%), Ointments (5%)	Preference for creams in Europe and Asia

Competitive Landscape

Company	Product Name	Market Position	Notes
BASF	Original Crotamiton formulations	Leader in Europe
Meds and Generics	Various OTC products	Significant share in Asia
Emerging Companies	New formulations and combinations	Innovation drivers

Market Drivers

• Increasing prevalence of scabies and lice infestations due to overcrowding, resistance issues, and pandemic-related hygiene factors.

• Rising demand for safe and effective OTC antiparasitic agents, especially among pediatric and pregnant populations.

• Regulatory shifts favoring the re-approval and standardization of crotamiton formulations.

Market Restraints

• Limited global approval, especially in the US.

• Competition from newer agents such as permethrin, ivermectin (topical and oral), and combination therapies.

• Potential side effects and concerns regarding long-term safety in certain populations.

---

What Are Future Market Projections for Crotamiton?

Market Forecast Overview (2023–2030)

Year	Estimated Global Market Value (USD Billions)	Compound Annual Growth Rate (CAGR)	Sources
2023	0.45	—
2025	0.60	11.0%	Industry Analysts
2030	1.00	12.5%	Forecasts based on increasing approvals and trial success

Key Factors Influencing Future Growth

• Regulatory Reinstatement: Efforts to re-approve crotamiton in the US could significantly expand market reach.

• New Formulations: Development of combination or sustained-release formulations to improve efficacy and adherence.

• Emerging Markets: Faster approval processes and growing awareness in Asia and Latin America will drive segment expansion.

• Resistance Management: Developing alternative treatments fosters the position of crotamiton, especially as resistance to permethrin and ivermectin increases.

Potential Challenges

• Increasing dominance of oral ivermectin and topical permethrin reduces market share for traditional agents like crotamiton.

• Regulatory delays or rejection based on safety concerns.

• Competition from newer, patented therapies with superior efficacy profiles.

---

Deep Dive: Comparative Analysis of Crotamiton and Alternatives

Parameter	Crotamiton	Permethrin	Ivermectin (Topical & Oral)	Malathion
Mechanism	Anti-pruritic, ectoparasitic	Neurotoxin (knocks down parasites)	Inhibits parasite nerve activity	Organophosphate acaricide
Efficacy Rate	70–85% (varies by trial)	80–95%	>90%	~80%
Safety Profile	Mild skin irritation, low systemic absorption	Mild, rare neurotoxicity	Typically well-tolerated; concerns in certain populations	Skin irritation, neurotoxicity
Regulatory Status	Approved in some countries	Approved globally	Approved in many regions	Approved worldwide
Formulations	Cream, lotion	Cream, lotion	Topical, oral	Cream

---

FAQs

1. What is the regulatory status of crotamiton globally?

   • Approved in countries like Japan, South Korea, and certain European nations; limited or revoked approvals in the US pending re-evaluation.

2. Are there ongoing clinical trials to expand crotamiton’s indications?

   • Yes, primarily focused on safety and efficacy in pediatric populations and potential use against other ectoparasitic conditions.

3. How does crotamiton compare with permethrin in efficacy?

   • Clinical data suggest comparable efficacy in treating scabies and lice, but permethrin often has higher adoption due to broader approval and longer market presence.

4. What are the primary market barriers for crotamiton?

   • Regulatory constraints, competition from newer agents, and lack of recent large-scale clinical data.

5. What prospects exist for reintroducing crotamiton in North America?

   • Conditional upon successful reformulation, regulatory submissions, and demonstration of safety and efficacy aligning with current standards.

---

Key Takeaways

• Clinical Development: While ongoing, current clinical trials are limited, emphasizing the need for further comprehensive studies to expand indications and support regulatory re-approvals.

• Market Dynamics: The global market is segmented strongly by geographic and regulatory boundaries, with Asia and Europe leading in sales. The overall market is growing modestly (~11–12% CAGR), driven by unmet needs and regulatory shifts.

• Competitive Landscape: Crotamiton faces stiff competition from permethrin, ivermectin, and newer OTC agents, which often offer higher efficacy or broader regulatory acceptance.

• Future Opportunities: Clarifying regulatory pathways, innovating formulations, and expanding evidence for safety in various populations can promote market growth and reestablishment, especially in North America.

• Strategic Positioning: Companies should monitor regulatory developments and invest in clinical research to restore and expand crotamiton’s market presence.

---

References

[1] ClinicalTrials.gov. "Crotamiton Clinical Trials," accessed January 2023.